Buy more to save!

NAD+ Nasal spray

Price range: $42.00 through $125.00
  • 0

Bacteriostatic water - 10ml

$6.38
  • 0

Bacteriostatic water

Price range: $2.98 through $6.38
  • 0

SS31

$69.50
  • 0
Research purpose vial of Epithalon 10mg blue label from Betterlife bioscience

Epithalon

Price range: $26.90 through $74.90
  • 0

Mots -C 10 mg

Original price was: $75.00.Current price is: $61.50.
  • 0

GHK-cu 100mg

Original price was: $80.00.Current price is: $48.00.
  • 0
This item: NAD+ Nasal spray
Price range: $42.00 through $125.00
$6.38
Price range: $2.98 through $6.38
$69.50
Price range: $26.90 through $74.90
Original price was: $75.00.Current price is: $61.50.
Original price was: $80.00.Current price is: $48.00.
Buy selected (1)
Save: $0.00 (0%)
Total price: $61.50 61.5

Description

NAD+

Chemical structure of NAD+
Chemical structure

Nicotinamide adenine dinucleotide is the oxidized form of NADH and a naturally occurring compound.

Research shows that NAD+ may be beneficial in improving muscle function, protecting cells of the nervous system, and generally reducing the effects of aging.

Low NAD+ has been linked to early aging in humans

Benefits reported from studies to include

Boosting energy levels.

Supporting neural development

Decreasing symptoms of aging and cognitive decline.

NAD+ is also reported to have the ability to increase cellular metabolism

NAD+ may protect neurons and improve cognitive function, with potential benefits for neurodegenerative diseases like Alzheimer’s and Parkinson’s

 

Addiction Recovery studies

NAD+ therapy has been used in studies and found to reduce withdrawal symptoms and cravings in addiction treatment, particularly for opioids, alcohol, and other substances.

Reducing Inflammation

NAD+ may help reduce chronic inflammation, a factor in many age-related diseases.

Additional information

Weight 0.02 lb

Reviews (0)

Be the first to review “NAD+ Nasal spray”

Your email address will not be published. Required fields are marked *

Reviews

There are no reviews yet.